Scorpion Therapeutics has a total of 42 patents globally, out of which none have been granted. Of these 42 patents, more than 80% patents are active. The United States of America seems to be the main focused R&D centre and also is the origin country of Scorpion Therapeutics.
Scorpion Therapeutics was founded in 2020. Scorpion Therapeutics was formed to extend the access and effect of precision medicine to more cancer patients. The company’s product, Precision Oncology 2.0 will be delivered by integrating cutting-edge technologies in target identification, medicinal chemistry, and translational medicine.
Do read about some of the most popular patents of Scorpion Therapeutics which have been covered by us in this article and also you can find Scorpion Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Scorpion Therapeutics patent portfolio.
How many patents does Scorpion Therapeutics have?
Scorpion Therapeutics has a total of 42 patents globally. These patents belong to 13 unique patent families. Out of 42 patents, 34 patents are active.
How Many Patents did Scorpion Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Scorpion Therapeutics Applications Filed | Scorpion Therapeutics Patents Granted |
| 2023 | 10 | – |
| 2022 | 6 | – |
| 2021 | 26 | – |
How many Scorpion Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Scorpion Therapeutics File in Different Countries?
Countries in which Scorpion Therapeutics Filed Patents
| Country | Patents |
| Argentina | 4 |
| Taiwan | 4 |
| Brazil | 2 |
| Mexico | 2 |
| Australia | 2 |
| Canada | 2 |
| New Zealand | 2 |
| Singapore | 2 |
| South Africa | 2 |
| Europe | 2 |
| Indonesia | 2 |
| Israel | 2 |
| Uruguay | 1 |
| Viet Nam | 1 |
Where are Research Centers of Scorpion Therapeutics Patents Located?
List of Scorpion Therapeutics patents
| Scorpion Therapeutics Patents | Title |
| EP4225445A2 | Heterocyclic Inhibitors Of Egfr And/Or Her2, For Use In The Treatment Of Cancer |
| EP4217070A1 | Pyrrolo[3,2-C]Pyridin-4-One Derivatives Useful In The Treatment Of Cancer |
| WO2023183601A1 | Methods Of Synthesizing Egfr Inhibitors |
| WO2023173083A1 | Tetrahydroindole Derivatives As Egfr And/Or Her2 Inhibtors Useful For The Treatment Of Cancer |
| WO2023018636A1 | Compounds That Inhibit Pi3K Isoform Alpha And Methods For Treating Cancer |
| WO2022265993A1 | Urea Derivatives Which Can Be Used To Treat Cancer |
| CA3198202A1 | Methods For Treating Cancer |
| CA3196712A1 | Pyrrolo[3,2-C]Pyridin-4-One Derivatives Useful In The Treatment Of Cancer |
| AU2021347288A9 | Pyrrolo[3,2-C]Pyridin-4-One Derivatives Useful In The Treatment Of Cancer |
| AU2021358596A1 | Heterocyclic Inhibitors Of Egfr And/Or Her2, For Use In The Treatment Of Cancer |
| IL301929A | Heterocyclic Inhibitors Of Egfr And/Or Her, For Use In The Treatment Of Cancer |
| IL301532A | Pyrrolo[3,2-C]Pyridin-4-One Derivatives Useful In The Treatment Of Cancer |
| SG11202302219RA | Pyrrolo[3,2-C]Pyridin-4-One Derivatives Useful In The Treatment Of Cancer |
| SG11202302664SA | Heterocyclic Inhibitors Of Egfr And/Or Her2, For Use In The Treatment Of Cancer |
| BR112023006531A2 | Heterocylic Egfr And/Or Her2 Inhibitors, For Use In The Treatment Of Cancer |
| VN97828A | Heterodimeric Inhibitors Of Epidermal Growth Factor Receptor (Egfr) And/Or Human Epidermal Growth Factor Receptor 2 (Her2) And Pharmaceutical Products Containing Them |
| AR126147A1 | Urea Derivatives To Treat Cancer |
| ID202306098A | Pyrolo[3,2-C]Pyridine-4-Ona Derivatives Which Are Useful In Cancer Treatment |
| MX2023004085A | Methods For The Treatment Of Cancer |
| BR112023005446A2 | Pyrolo[3,2-C]Pyridin-4-One Derivatives Useful In The Treatment Of Cancer |
| ID202304999A | Egfr And/Or Her2 Heterosyclic Inhibitors, For Use In The Treatment Of Cancer |
| MX2023003362A | Pyrrolo[3,2-C]Pyridin-4-One Derivatives Useful In The Treatment Of Cancer |
| TW202317526A | Methods For Treating Cancer |
| ZA202303873A | Pyrrolo[3,2-C]Pyridin-4-One Derivatives Useful In The Treatment Of Cancer |
| ZA202304505A | Heterocyclic Inhibitors Of Egfr And/Or Her2, For Use In The Treatment Of Cancer |
| UY39819A | Methods To Treat Cancer |
| AR123760A1 | Methods To Treat Cancer |
| AR123657A1 | Methods For The Treatment Of Cancer |
| AR123576A1 | Methods To Treat Cancer |
| TW202229272A | Methods For Treating Cancer |
| TW202229282A | Methods For Treating Cancer |
| TW202227063A | Methods For Treating Cancer |
| NZ799055A | Heterocyclic Inhibitors Of Egfr And/Or Her2, For Use In The Treatment Of Cancer |
| NZ798381A | Pyrrolo[3,2-C]Pyridin-4-One Derivatives Useful In The Treatment Of Cancer |
| WO2022072645A3 | Pyrrolopyrolidinone And Pyrroloazepinone Derivatives For Use In Treating Cancer |
| WO2022197913A1 | Bicyclic Derivatives Which Can Be Used To Treat Cancer |
| WO2022076831A3 | Heterocyclic Inhibitors Of Egfr And/Or Her2, For Use In The Treatment Of Cancer |
| WO2022098992A1 | Use Of Macrocyclic Compounds In Methods Of Treating Cancer |
| WO2022094271A1 | Methods For Treating Cancer |
| WO2022072632A1 | Bicyclic Compounds For Use In The Treatment Cancer |
| WO2022072634A1 | Bicyclic Compounds For Use In The Treatment Cancer |
| WO2022066734A1 | Pyrrolo[3,2-C]Pyridin-4-One Derivatives Useful In The Treatment Of Cancer |
What are Scorpion Therapeutics key innovation segments?
What Technologies are Covered by Scorpion Therapeutics?
The chart below distributes patents filed by Scorpion Therapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where Scorpion Therapeutics thinks it’s important to protect particular technology inventions.
R&D Focus: How has Scorpion Therapeutics search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Scorpion Therapeutics?